Do analysts prefer GCTK or ICU?

SeaStar Medical has a consensus target price of $8.00, indicating a potential upside of 143.90%. Given SeaStar Medical's stronger consensus rating and higher probable upside, analysts plainly believe SeaStar Medical is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SeaStar Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate GCTK or SURG?

SurgePays has a consensus price target of $5.00, suggesting a potential upside of 851.29%. Given SurgePays' stronger consensus rating and higher probable upside, analysts clearly believe SurgePays is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is GCTK or SURG more profitable?

GlucoTrack has a net margin of 0.00% compared to SurgePays' net margin of -64.91%. GlucoTrack's return on equity of -581.98% beat SurgePays' return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -581.98% -220.10% SurgePays -64.91% -967.32% -310.16%

Does the media prefer GCTK or SURG?

In the previous week, GlucoTrack and GlucoTrack both had 2 articles in the media. GlucoTrack's average media sentiment score of 0.96 beat SurgePays' score of 0.77 indicating that GlucoTrack is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlucoTrack 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SurgePays 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer GCTK or MBAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, GCTK or MBAI?

Check-Cap is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GlucoTrack N/A N/A -$19.39M -$18.04 N/A Check-Cap N/A N/A $4.14M -$2.77 N/A

Is GCTK or MBAI more profitable?

Check-Cap's return on equity of 0.00% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -581.98% -220.10% Check-Cap N/A N/A N/A

Does the media refer more to GCTK or MBAI?

In the previous week, GlucoTrack and GlucoTrack both had 2 articles in the media. GlucoTrack's average media sentiment score of 0.96 beat Check-Cap's score of 0.94 indicating that GlucoTrack is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlucoTrack 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Check-Cap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALUR or GCTK?

In the previous week, GlucoTrack had 1 more articles in the media than Allurion Technologies. MarketBeat recorded 2 mentions for GlucoTrack and 1 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 1.42 beat GlucoTrack's score of 0.96 indicating that Allurion Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allurion Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GlucoTrack 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer GCTK or LFWD?

Lifeward has a consensus price target of $10.00, indicating a potential upside of 37.36%. Given Lifeward's stronger consensus rating and higher probable upside, analysts clearly believe Lifeward is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lifeward 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is GCTK or LFWD more profitable?

GlucoTrack has a net margin of 0.00% compared to Lifeward's net margin of -123.66%. Lifeward's return on equity of -243.14% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -581.98% -220.10% Lifeward -123.66% -243.14% -97.39%

GlucoTrack (GCTK) Competitors

$0.67 +0.00 (+0.67%)

Closing price 04:00 PM Eastern

Extended Trading

$0.67 +0.00 (+0.54%)

As of 07:45 PM Eastern

Compare

GCTK vs. ICU, SURG, MBAI, ALUR, and LFWD

Should you buy GlucoTrack stock or one of its competitors? MarketBeat compares GlucoTrack with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GlucoTrack include SeaStar Medical (ICU), SurgePays (SURG), Check-Cap (MBAI), Allurion Technologies (ALUR), and Lifeward (LFWD). These companies are all part of the "medical equipment" industry.

How does GlucoTrack compare to SeaStar Medical?

GlucoTrack (NASDAQ:GCTK) and SeaStar Medical (NASDAQ:ICU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

SeaStar Medical has a consensus target price of $8.00, indicating a potential upside of 143.90%. Given SeaStar Medical's stronger consensus rating and higher probable upside, analysts plainly believe SeaStar Medical is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SeaStar Medical has higher revenue and earnings than GlucoTrack. SeaStar Medical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A
SeaStar Medical	$1.23M	10.67	-$12.15M	-$4.80	N/A

GlucoTrack has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, SeaStar Medical has a beta of -1.05, meaning that its share price is 205% less volatile than the broader market.

In the previous week, GlucoTrack had 1 more articles in the media than SeaStar Medical. MarketBeat recorded 2 mentions for GlucoTrack and 1 mentions for SeaStar Medical. SeaStar Medical's average media sentiment score of 1.89 beat GlucoTrack's score of 0.96 indicating that SeaStar Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
GlucoTrack	Positive
SeaStar Medical	Very Positive

GlucoTrack has a net margin of 0.00% compared to SeaStar Medical's net margin of -828.62%. SeaStar Medical's return on equity of -146.29% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
SeaStar Medical	-828.62%	-146.29%	-96.48%

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are held by institutional investors. 2.2% of GlucoTrack shares are held by company insiders. Comparatively, 0.7% of SeaStar Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

SeaStar Medical beats GlucoTrack on 9 of the 15 factors compared between the two stocks.

How does GlucoTrack compare to SurgePays?

GlucoTrack (NASDAQ:GCTK) and SurgePays (NASDAQ:SURG) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 6.9% of SurgePays shares are held by institutional investors. 2.2% of GlucoTrack shares are held by company insiders. Comparatively, 29.1% of SurgePays shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, GlucoTrack and GlucoTrack both had 2 articles in the media. GlucoTrack's average media sentiment score of 0.96 beat SurgePays' score of 0.77 indicating that GlucoTrack is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GlucoTrack	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SurgePays	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

GlucoTrack has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, SurgePays has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

GlucoTrack has a net margin of 0.00% compared to SurgePays' net margin of -64.91%. GlucoTrack's return on equity of -581.98% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
SurgePays	-64.91%	-967.32%	-310.16%

SurgePays has a consensus price target of $5.00, suggesting a potential upside of 851.29%. Given SurgePays' stronger consensus rating and higher probable upside, analysts clearly believe SurgePays is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

GlucoTrack has higher earnings, but lower revenue than SurgePays. SurgePays is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A
SurgePays	$56.96M	0.23	-$36.07M	-$1.94	N/A

Summary

GlucoTrack beats SurgePays on 8 of the 14 factors compared between the two stocks.

How does GlucoTrack compare to Check-Cap?

GlucoTrack (NASDAQ:GCTK) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

GlucoTrack has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Check-Cap has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 2.2% of GlucoTrack shares are owned by company insiders. Comparatively, 0.5% of Check-Cap shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Check-Cap's return on equity of 0.00% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
Check-Cap	N/A	N/A	N/A

Check-Cap is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A

In the previous week, GlucoTrack and GlucoTrack both had 2 articles in the media. GlucoTrack's average media sentiment score of 0.96 beat Check-Cap's score of 0.94 indicating that GlucoTrack is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GlucoTrack	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GlucoTrack beats Check-Cap on 5 of the 9 factors compared between the two stocks.

How does GlucoTrack compare to Allurion Technologies?

Allurion Technologies (NYSE:ALUR) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Allurion Technologies presently has a consensus target price of $3.00, suggesting a potential upside of 250.88%. Given Allurion Technologies' stronger consensus rating and higher possible upside, equities research analysts plainly believe Allurion Technologies is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Allurion Technologies has higher revenue and earnings than GlucoTrack. Allurion Technologies is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21M	0.74	-$7.20M	-$1.75	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A

21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 8.1% of Allurion Technologies shares are held by company insiders. Comparatively, 2.2% of GlucoTrack shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

GlucoTrack has a net margin of 0.00% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
GlucoTrack	N/A	-581.98%	-220.10%

In the previous week, GlucoTrack had 1 more articles in the media than Allurion Technologies. MarketBeat recorded 2 mentions for GlucoTrack and 1 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 1.42 beat GlucoTrack's score of 0.96 indicating that Allurion Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allurion Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GlucoTrack	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allurion Technologies has a beta of -0.18, suggesting that its share price is 118% less volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

Summary

Allurion Technologies beats GlucoTrack on 11 of the 15 factors compared between the two stocks.

How does GlucoTrack compare to Lifeward?

GlucoTrack (NASDAQ:GCTK) and Lifeward (NASDAQ:LFWD) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 26.8% of Lifeward shares are held by institutional investors. 2.2% of GlucoTrack shares are held by company insiders. Comparatively, 1.5% of Lifeward shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Lifeward has a consensus price target of $10.00, indicating a potential upside of 37.36%. Given Lifeward's stronger consensus rating and higher probable upside, analysts clearly believe Lifeward is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lifeward	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

GlucoTrack has higher earnings, but lower revenue than Lifeward. Lifeward is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A
Lifeward	$22.03M	0.93	-$19.91M	-$19.66	N/A

GlucoTrack has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Lifeward has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

In the previous week, Lifeward had 4 more articles in the media than GlucoTrack. MarketBeat recorded 6 mentions for Lifeward and 2 mentions for GlucoTrack. Lifeward's average media sentiment score of 1.47 beat GlucoTrack's score of 0.96 indicating that Lifeward is being referred to more favorably in the news media.

Company	Overall Sentiment
GlucoTrack	Positive
Lifeward	Positive

GlucoTrack has a net margin of 0.00% compared to Lifeward's net margin of -123.66%. Lifeward's return on equity of -243.14% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
Lifeward	-123.66%	-243.14%	-97.39%

Summary

Lifeward beats GlucoTrack on 9 of the 15 factors compared between the two stocks.

Get GlucoTrack News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GCTK vs. The Competition

Export

Metric	GlucoTrack	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.14M	$8.16B	$6.47B	$12.54B
Dividend Yield	N/A	2.61%	2.69%	5.22%
P/E Ratio	-0.04	15.39	22.39	24.18
Price / Sales	N/A	7.06	520.79	112.26
Price / Cash	N/A	17.10	41.34	57.13
Price / Book	0.24	3.53	9.84	6.72
Net Income	-$19.39M	$224.05M	$3.57B	$337.19M
7 Day Performance	4.46%	-1.09%	-1.16%	0.48%
1 Month Performance	-16.83%	0.34%	3.85%	5.07%
1 Year Performance	-92.24%	-0.29%	27.40%	34.25%

GlucoTrack Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GCTK GlucoTrack	1.0728 of 5 stars	$0.67 +0.7%	N/A	-91.3%	$4.14M	N/A	N/A	5
ICU SeaStar Medical	3.0199 of 5 stars	$3.59 +0.3%	$8.00 +122.8%	-70.1%	$14.31M	$1.23M	N/A	2	Positive News
SURG SurgePays	3.0757 of 5 stars	$0.55 +9.0%	$5.00 +807.4%	-81.3%	$12.70M	$56.96M	N/A	40	Short Interest Decrease
MBAI Check-Cap	0.2751 of 5 stars	$1.70 -1.2%	N/A	N/A	$12.54M	N/A	N/A	80	Gap Down
ALUR Allurion Technologies	1.954 of 5 stars	$0.80 flat	$3.00 +275.0%	-73.5%	$12.00M	$17.21M	N/A	501	News Coverage Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GCTK) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GlucoTrack (GCTK) Competitors

GCTK vs. ICU, SURG, MBAI, ALUR, and LFWD

How does GlucoTrack compare to SeaStar Medical?

Summary

How does GlucoTrack compare to SurgePays?

Summary

How does GlucoTrack compare to Check-Cap?

Summary

How does GlucoTrack compare to Allurion Technologies?

Summary

How does GlucoTrack compare to Lifeward?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GlucoTrack (GCTK) Competitors

GCTK vs. ICU, SURG, MBAI, ALUR, and LFWD

How does GlucoTrack compare to SeaStar Medical?

Do analysts prefer GCTK or ICU?

Which has better valuation and earnings, GCTK or ICU?

Which has more risk & volatility, GCTK or ICU?

Does the media prefer GCTK or ICU?

Is GCTK or ICU more profitable?

Do insiders and institutionals believe in GCTK or ICU?

Summary

How does GlucoTrack compare to SurgePays?

Do institutionals & insiders hold more shares of GCTK or SURG?

Does the media prefer GCTK or SURG?

Which has more volatility and risk, GCTK or SURG?

Is GCTK or SURG more profitable?

Do analysts rate GCTK or SURG?

Which has better valuation & earnings, GCTK or SURG?

Summary

How does GlucoTrack compare to Check-Cap?

Which has more risk and volatility, GCTK or MBAI?

Do insiders & institutionals believe in GCTK or MBAI?

Do analysts prefer GCTK or MBAI?

Is GCTK or MBAI more profitable?

Which has better valuation & earnings, GCTK or MBAI?

Does the media refer more to GCTK or MBAI?

Summary

How does GlucoTrack compare to Allurion Technologies?

Do analysts prefer ALUR or GCTK?

Which has stronger valuation & earnings, ALUR or GCTK?

Do insiders & institutionals have more ownership in ALUR or GCTK?

Is ALUR or GCTK more profitable?

Does the media favor ALUR or GCTK?

Which has more risk and volatility, ALUR or GCTK?

Summary

How does GlucoTrack compare to Lifeward?

Do institutionals and insiders believe in GCTK or LFWD?

Do analysts prefer GCTK or LFWD?

Which has preferable earnings & valuation, GCTK or LFWD?

Which has more volatility and risk, GCTK or LFWD?

Does the media refer more to GCTK or LFWD?

Is GCTK or LFWD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools